This trial is testing a new treatment for leukemia that uses the patient's own immune cells. The first part of the trial will test how safe it is, and the second part will test how well it works.
2 Primary · 9 Secondary · Reporting Duration: I year post HCT
37 Total Participants · 1 Treatment Group
Primary Treatment: CD33CART · No Placebo Group · Phase 1 & 2
Age 1 - 35 · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: